Immunogenicity of fractional doses of tetravalent A/C/Y/W135 meningococcal polysaccharide vaccine:results from a randomized non-inferiority controlled trial in Uganda by Guerin, Philippe J. et al.
Immunogenicity of Fractional Doses of Tetravalent
A/C/Y/W135 Meningococcal Polysaccharide Vaccine:
Results from a Randomized Non-Inferiority Controlled
Trial in Uganda
Philippe J. Guerin1,2,3*, Lisbeth M. Næss2,3, Carole Fogg1, Einar Rosenqvist2,3, Loretxu Pinoges1, Francis
Bajunirwe1,4, Carolyn Nabasumba1, Ray Borrow5, Leif O. Frøholm2, Salah Ghabri1, Vincent Batwala1,4,
Rogers Twesigye1, Ingeborg S. Aaberge2,3, John-Arne Røttingen2,3,6, Patrice Piola1, Dominique A.
Caugant2,3,7
1 Epicentre, Paris, France, 2Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway, 3Centre for Prevention of Global Infections,
University of Oslo, Oslo, Norway, 4Mbarara University of Science and Technology, Mbarara, Uganda, 5Health Protection Agency, Manchester, United Kingdom,
6Norwegian Knowledge Centre for the Health Services, Oslo, Norway, 7Department of Oral Biology, University of Oslo, Oslo, Norway
Abstract
Background: Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan
Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with
polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the
use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine.
Methods and Findings: We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2–19 years old in
Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10).
Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-
vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder
was defined as a subject with a $4-fold increase in SBA against a target strain from each serogroup and SBA titer $128. For
serogroup W135, 94% and 97% of the vaccinees in the 1/5- and 1/10-dose arms, respectively, were responders, versus 94%
in the full-dose arm; for serogroup A, 92% and 88% were responders, respectively, versus 95%. Non-inferiority was
demonstrated between the full dose and both fractional doses in SBA seroresponse against serogroups W135 and Y, in total
population analysis. Non-inferiority was shown between the full and 1/5 doses for serogroup A in the population non-
immune prior to vaccination. Non-inferiority was not shown for any of the fractionate doses for serogroup C. Safety and
tolerability data were favourable, as observed in other studies.
Conclusions: While the advent of conjugate A vaccine is anticipated to largely contribute to control serogroup A outbreaks
in Africa, the scale-up of its production will not cover the entire ‘‘Meningitis Belt’’ target population for at least the next 3 to
5 years. In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be
considered as an alternative in mass vaccination campaigns.
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Introduction
Sub-Saharan African countries in the ‘‘Meningitis Belt,’’
situated between Ethiopia and Senegal, face epidemics of
meningococcal meningitis almost every year [1]. Following the
current World Health Organization (WHO) recommendation,
mass vaccination campaigns with polysaccharide meningococcal
vaccine are implemented solely to control the spread of the
epidemic [2]. Until recently, Neisseria meningitidis serogroup A has
been the main organism causing those epidemics, while other
serogroups play a minor epidemiological role.
Following W135 outbreaks in Saudi Arabia in 2000 and 2001,
cases of N. meningitidis serogroup W135 were reported in Burkina
Faso in 2001, resulting in the first large W135 epidemic in that
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country in 2002 [3,4]. This outbreak raised serious concerns
regarding the availability of a vaccine protecting against that
serogroup, i.e., a tetravalent A/C/Y/W135 polysaccharide
vaccine (PSV). Mass vaccination of the population in Burkina
Faso with the tetravalent PSV was not possible because of the
global shortage in supply, in addition to its cost. In 2003,
GlaxoSmithKline began producing a trivalent A/C/W135
polysaccharide vaccine for approximately USD1.50/dose, which
was used in Burkina Faso in another epidemic the same year [5].
Since then however, availability and affordability of the tetravalent
or trivalent polysaccharide vaccines remain uncertain every year.
The production of the bivalent A/C polysaccharide vaccine has been
considerably reduced since 2005 and the quantity of vaccines to be
produced in the next 3 to 5 years is uncertain [6,7]. In case of
simultaneous large outbreaks in different countries, the supply of
meningococcal PSV for the coming meningitis seasons is unlikely to
be sufficient to cover vaccination needs (Perea W., WHO, personal
communication, March 2008). Conjugate meningococcal vaccines,
are not expected to be available and affordable in large quantities to
cover the need for Africa over the next several years [7–9].
The current dose of the licensed tetravalent PSV developed in
the 1970s contains 50 mg of each polysaccharide component.
Studies in the 1970s and 1980s have shown that lower doses of
polysaccharide were as effective as 50 mg in inducing bactericidal
antibody levels that should be protective against disease in adults
in the US [10–14].
To test if fractionate doses might also be protective in an African
population and in younger age groups, we conducted a clinical
vaccine trial in Uganda to evaluate the potential use of fractional
doses of meningococcal tetravalent PSV to control disease
outbreak caused by N. meningitidis. The study population selected
for the trial was 2–19 years of age, i.e., the population at highest
risk of the disease and the primary target of mass vaccination
campaigns in Africa during epidemics [15].
Methods
Study design and population
The study design was a randomized, single-blind controlled
trial. Three arms were defined in the trial: group 1 received a dose
of 50 mg of each component of tetravalent PSV, i.e., a full dose of
the licensed vaccine; group 2 received a 1/5 volume of tetravalent
PSV (10 mg of each component); and group 3 received a 1/10
volume of tetravalent PSV (5 mg of each component).
The study was conducted in the rural area of Kinoni,
Rwampara County, Mbarara District, Uganda. This location
was chosen on the basis of the following criteria: i, this area had
not experienced recent epidemics of meningococcal meningitis; ii,
the study population was considered to be stable; iii, the health
subdistrict was considered a suitable site for this interventional
study because it has a long-standing collaboration with Mbarara
University, Department of Community Health.
The recruitment of participants for the clinical trial was done on a
voluntary basis. Volunteers aged 2–19 years old were recruited in
proportions matching the Ugandan age distribution of the 2–19
years old extracted from the ‘‘2002/03 Uganda National House-
hold Survey.’’ Volunteers were residents of Mbarara district, living
within a 15-km radius of the vaccination site, with no plans of
moving from the area during the study period. Community
awareness meetings were held with local leaders and field workers
from the study team, who then went house to house to get a list of
people who were willing to participate. Participants came to the
study site on a planned date. Refusal rates were not recorded in
order to avoid unnecessary pressure on the communities.
Objectives and outcomes
This study aimed to demonstrate non-inferiority in the immune
response of doses corresponding to 1/5 and/or 1/10 of the
amount of the full dose of a licensed A/C/Y/W135 polysaccha-
ride vaccine (Menomune, Sanofi Aventis) and to evaluate the
tolerability of these vaccinations. The primary endpoint was the
proportion of responders defined by immunogenicity criteria at
four weeks after vaccination based on SBA titers. The secondary
endpoint considered the IgG response (Elisa).
Sample size calculation
The sample size was calculated by choosing a one-sided 0.05 level
of significance and power of 80%. Expecting equal proportions of
responders in all groups given the vaccine being 80%, and assuming a
non-inferiority margin of 10%, this gave a required sample size n of
198 persons in each group. Because the reference group (full dose)
was used for two comparisons, a correction of (N~n1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
number of comparisons
p
) was applied [16], bringing that group
to 280. The calculations have been performed using nQuery Advisor.
Randomization and allocations
Following consent and a clinical examination, each subject was
randomly allocated to one of the 3 dosage groups. The allocation
schedule was computer-generated, using a block randomization
method, stratified by age group (2 to 4; 5 to 9; 10 to 14 and 15 to 19
years). The researchers responsible for seeing the volunteers allocated
the next available number on entry into the trial. The vaccination
was given subcutaneously using low-volume syringes (0.5mL BD
Micro-Fine insulin syringes), by the same nurse throughout the study,
without participant knowledge of the dosage received. A single dose
vaccine Menomune vial was used per volunteer, numbered with the
study number and stored after vaccination. A full dose injection
corresponded to 0.5ml of the vaccine, 1/5 of the dose corresponded
to 0.1ml and 1/10 of the dose to 0.05ml.
Safety
Volunteers were observed for 1 hour following vaccination for
adverse events. Safety and tolerability data were collected for all
Author Summary
Meningitis are infections of the lining of the brain and spinal
cord and can cause high fever, blood poisoning, and brain
damage, as well as result in death in up to 10% of cases.
Epidemics of meningitis occur almost every year in parts of
sub-Saharan Africa, throughout a high-burden area span-
ning Senegal to Ethiopia dubbed the ‘‘Meningitis Belt.’’
Most epidemics in Africa are caused by Neisseria meningi-
tidis (mostly serogroup A and W135). Mass vaccination
campaigns attempt to control epidemics by administering
meningococcal vaccines targeted against these serogroups,
among others. However, global shortages of these vaccines
are currently seen. We studied the use of fractional (1/5 and
1/10) doses of a licensed vaccine to assess its non-inferiority
compared with the normal full dose. In a randomized trial in
Uganda, we found that immune response and safety using
a 1/5 dose were comparable to full dose for three
serogroups (A, Y, W135), though not a fourth (C). In light
of current shortages of meningococcal vaccines and their
importance in fighting meningitis epidemics around the
world, we suggest fractional doses be taken under
consideration in mass vaccination campaigns.
Fractional Doses Meningococcal Vaccine
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volunteers during the 4 weeks following the injection. Safety data
were collected during weekly interviews. The intensity of the
adverse events was evaluated by clinicians, members of the study
team and classified as ‘‘mild,’’ ‘‘moderate,’’ or ‘‘severe’’ using the
Common Toxicity Criteria (CTC) grading (http://ctep.cancer.
gov/reporting/CTC-3.html, US National Cancer Institute).
Laboratory analysis
Serum samples (10 mL of whole blood) were collected from each
volunteer immediately before vaccination and 4 weeks later, stored
at280uC from the trial to the laboratories. Assays were carried out
blinded at the Norwegian Institute of Public Health (NIPH).
Immune responses to the different doses of the TPSV were analyzed
in serum bactericidal assays (SBA) and enzyme-linked immunosor-
bent assays (ELISA). SBA was performed against four target strains
of the A, C, W135, and Y serogroups: A: F8238 (4/21:P1.20,9); C:
C11 (16:P1.7-1,1); W135: M01240070 (NT:P1.18-1,3); and Y:
M00242975 (2a:P1.5,2). Heat-inactivated test sera were diluted 2-
fold in microtiter plates (starting at serum dilution of 1:4) and
incubated for 60 min with bacteria and baby rabbit complement
(Pel-Freeze) before plating onto agar plates [17]. Colony-forming
units were counted (Sorcerer colony counter, Perceptive Instru-
ments), and bactericidal antibody titers were expressed as the
reciprocal of the final serum dilution giving$50% killing compared
with controls (inactive complement/no test serum). External quality
control of SBA measurements was performed by Manchester
Health Protection Agency (HPA) by analyzing in parallel
approximately 10% of samples taken before vaccination and four
weeks later. IgG antibodies to each separate polysaccharide A, C, Y,
and W135 were measured in ELISA as described by Carlone et al.
[18] and modified according to Joseph et al. using the CDC 1992
standard (NIBSC code 99/706) [19].
Carriage study
Tonsillo-pharyngeal samples were collected from the volunteers
before vaccination and four weeks later. The technique and results
of this carriage study are published elsewhere [20]. Volunteers
found to be carriers of N. meningitidis of a homologous serogroup at
any time between the vaccination and four weeks later were
excluded from the analysis of response to that polysaccharide.
Statistical analysis
For computational purposes, titers ,4 were assigned a value of
2. A subject with SBA titer $128 was defined as putatively
protected [21]. The Modified Intention To Treat (MITT)
population included all randomized and exposed subjects with a
defined SBA titer before vaccination and four weeks later. The Per
Protocol (PP) population excluded subjects from the MITT
presenting protocol violation. Some immunogenicity measures
were not planned and described in the statistical analysis of the
protocol. For the benefit of the study, the scientific committee
coordinating the trial suggested additional statistical analyses: i, the
principal criteria to define a responder was reinforced, as not only
a 4-fold or greater increase in antibody titer between pre- and
post-immunization sera, but also an SBA titer $128 four weeks
after vaccination; ii, we also considered an exploratory population
of the MITT, namely the ‘‘non-immune population’’ before
vaccination, defined as individuals with SBA titers ,128 before
vaccination, which is considered the threshold of non-immunity
[21–25]. Baseline characteristics were summarized by treatment
groups using descriptive statistics (Geometric Mean Titer [GMT]
and Geometric Mean Concentration [GMC)] were used for the
analysis of the SBA titers and IgG concentrations). McNemar’s test
was used to compare matched pair titer data before vaccination
and four weeks later.
The proportion of adequate responses in each group was
expressed as a percentage (‘‘response to vaccine rate’’). A 95%
confidence interval was calculated for the observed difference in
response proportion (full versus fractional dose), and if the upper
limit was ,10%, the fractional dose was considered non-inferior
to the full dose. These analyses were performed on MITT, PP, and
non-immune subsets of the MITT.
We performed a logistic regression to look at the impact of age
among responders by serogroup and by arm. Age was considered
in two groups of interest (#5 and .5 years of age) knowing that in
previous studies, eliciting an immune response under 5 was the
most critical [11,26].
Data were double-entered using Epidata 3.0 (The EpiData
Association, Odense, Denmark). Statistical analyses were per-
formed using STATA 9 (College Station, Texas, USA).
Ethics
Written informed consent in the local language was obtained
from the parents or guardians of every volunteer ,18 years of age
or by the volunteers themselves if .18 years. The study was
approved by the Faculty Research and Ethics Committee of the
Mbarara University of Science and Technology (MUST), the
MUST Institutional Review Board, the Uganda National
Committee of Science and Technology, and the Regional
Committee for Medical Research Ethics in Norway. The trial
was registered at Clinicaltrials.gov (NCT00271479).
Results
Study groups
Between 5 July 2004 and 22 September 2004, 763 volunteers
from the Kinoni community in Mbarara, Uganda were screened
(Figure 1). Among them, 750 volunteers were included, with 291
randomized to the full-dose vaccine arm, 225 to the 1/5-dose arm,
and 234 to the 1/10-dose arm.
The demographic and serological baseline characteristics of the
population at inclusion before vaccination are displayed in Table 1.
For each serogroup, volunteers were not considered in the analyses
if an SBA value was missing for either before vaccination or four
weeks later. No differences were observed between arms for
demographic and serological data.
Natural immunity toward N. meningitidis serogroups A, C, Y, and
W135 before vaccination in the study population was measured by
the proportion of volunteers with SBA titers $128 before
vaccination: 51.4% (382/743) for serogroup A; 22.6% (168/744)
for serogroup W135; 6.2% (45/729) for serogroup C, and 2.3%
(17/741) for serogroup Y.
Immunologic response
Protocol deviations leading to exclusion of population are described
in Table 2. The primary end point, i.e. proportions of responders per
arm and per analyses are reported in Table 3. For serogroup W135,
94.4% (168/178) of the non-immune, vaccinated subjects in the 1/5-
dose arm, and 97.2% (172/177) in the 1/10-dose arm, were
responders, compared with 93.7% (207/221) in the full-dose arm. For
serogroup A, 92.2% (94/102) and 88.3% (98/111) of non-immune
vaccinees in the 1/5- and 1/10-dose arms, respectively, were
responders, compared with 94.6% (140/148) in the full-dose arm.
Non-inferiority was demonstrated for serogroups W135 and Y
(full dose versus each fractional dose in MITT analyses), but was
statistically rejected for serogroups A and C (Table 4). When
analyzing only the non-immune population, non-inferiority was
Fractional Doses Meningococcal Vaccine
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also demonstrated for full versus 1/5 doses for serogroups A (2.4%
[95% confidence interval, 23.9 to 8.8%]), W135 (20.7% [95%
confidence interval, 25.4 to 3.9%]), and Y (2.6% [95% confidence
interval, 24.1 to 9.3%]), but not for serogroup C (11.5% [95%
confidence interval, 5.4 to 17.5%]) (Table 4). When considering the
response by age group (logistic regression), children under 5 had a
lower chance of positive response compared to older ones for
serogroup W135 (significant only for full dose arm), serogroup C
(significant for full dose and 1/5 dose arms) and for serogroup Y
(significant for 1/10 dose arm) (Table 5). For serogroup A, although
not significant, fractional doses seem to elicit a better response in
children under 5.
The secondary immunogenicity criterion based on ELISA data
is reported on Figure 2. For each serogroup and each dose of
vaccine, the geometric means of IgG concentrations showed no
difference between arms before vaccination but a significant
Figure 1. Consort flowchart.
doi:10.1371/journal.pntd.0000342.g001
Table 1. Demographic and serological baseline characteristics
Full dose (n =291) 1/5 dose (n =224)* 1/10 dose (n =235)*
Age (years) Median (IQR) 9.1 (5.1–13.1) 9.1 (5.1–13.1) 9.1 (5.1–14.1)
Sex Ratio (M/F) 0.89 (137/154) 1.06 (115/109) 0.90 (111/124)
Weight (kg) Median (IQR) 25 (16–37) 25 (17–37) 25 (17–39)
Height (cm) Median (IQR) 128.0 (107–146.5) 127.1 (110–146.5) 129.8 (108.5–149.4)
SBA A titers GMT (GSD) 41.6 (21.6) 58.7 (20.9) 48.8 (21.0)
GMC IgG mg/mL ELISA A GMC (GSD) 2.6 (2.4) 2.8 (2.3) 2.4 (2.4)
SBA W135 titers GMT (GSD) 7.1 (10.0) 6.0 (8.6) 7.1 (10.1)
GMC IgG mg/mL ELISA W135 GMC (GSD) 2.7 (2.5) 2.9 (2.4) 2.9 (2.3)
SBA C titers GMT (GSD) 2.7 (3.5) 2.8 (3.9) 3.5 (5.3)
GMC IgG mg/mL ELISA C GMC (GSD) 0.9 (2.4) 1.0 (2.4) 1.0 (2.3)
SBA Y titers GMT (GSD) 2.2 (1.9) 2.7 (3.8) 2.2 (2.0)
GMC IgG mg/mL ELISA Y GMC (GSD) 2.9 (2.4) 3.1 (2.4) 3.1 (2.3)
*One patient randomized in the 1/5-dose group received 1/10 of the dose.
GSD: Geometric Standard Deviation.
doi:10.1371/journal.pntd.0000342.t001
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difference four weeks later with full dose greater than both 1/5 and
1/10 doses. Statistically significant differences were observed
between the vaccination and four weeks later for each dose and
each serogroup (p,0.0001 for all comparisons).
Adverse events
A total of 158 volunteers reported at least one adverse event
during the 4 weeks after vaccination (171 total adverse events,
Table 6). No significant statistical difference was observed among
the three dose arms (x2 test, p = 0.42). The most commonly
reported adverse events were upper respiratory tract infections
(URTI) (57%) and malaria (20%). Five severe adverse events were
recorded: one severe case of malaria, one severe episode of
seizures, and 3 severe URTI, but these events were not considered
to be related to the vaccination. Three adverse events considered
‘‘probably related’’ were reported and classified as mild (2 subjects
with fever and 1 with headache).
Quality control
External quality control of the SBA titer measurements showed
no significant difference with regard to responders for serogroup A
(McNemar pair matched test, p = 0.63), serogroup C (p= 0.06),
and serogroup Y (p= 0.41). For serogroup W135, the difference
was statistically significant (p,0.001).
Discussion
SBA is the accepted correlate of protection for meningococcal
disease. In the MITT analysis of this study, non-inferiority was
demonstrated between full and 1/5 and 1/10 fractional doses of
TPSV in SBA response against the meningococcal serogroups
W135 and Y. Non-inferiority was only shown between the full and
1/5 doses for serogroup A in the pre-vaccination, non-immune
population. Non-inferiority was rejected for serogroup C in all
analyses. Safety and tolerability data were favourable, as observed
with TPSV in other studies [27,28].
In analyzing the proportion of responders per serogroup, we
observed a decline in response for serogroup A and C from the full
versus 1/5 dose, and this decrease was accentuated versus the 1/
10 dose. For serogroup A, which is the most important serogroup
to protect against in sub-Saharan Africa, the response in the
MITT analysis decreased from 86% to 77%. Several elements
must be considered in the interpretation of these results. A notable
proportion of volunteers (51.4%) had high SBA titers against
serogroup A prior to vaccination, presumably resulting from
natural immunity. In demonstrating non-inferiority between the
full and 1/5 dose groups in the non-immune population, the
difference in responses occurred mainly in the naturally immune
subgroup. These results suggest that the full dose may elicit higher
increase in SBA titers for subjects with pre-vaccination SBA titers
$128 compared with 1/5 of the dose. However, assuming that a
post-vaccination SBA titer$128 is a proxy for vaccine efficacy, we
believe that 1/5 of the dose induced an acceptable increase of SBA
for non-immune populations, although it did not strictly meet the
criteria we designed for the total population. When considering
the response for children under five, overall fractional doses do not
affect the chance of response compared to full dose. For serogroup
A, the response could be possibly better in children under five with
fractional doses, though the study was not powered to demonstrate
this hypothesis.
For all serogroups, the IgG concentrations decreased with
fractional doses. However, the SBA titer/IgG ratios showed similar
results between arms for all serogroups (data not shown), indicating a
higher proportion of bactericidal antibodies in fractional doses. This
could be due to differences in antibody avidity, though this
hypothesis would require further studies. In an epidemic response
setting, the goal of a mass vaccination campaign is short term
immunity-basically protection through to the end of the epidemic
season. Therefore, longer duration of protection (presumably
predicted by higher titers) is a less important issue.
Licensed meningococcal polysaccharide vaccines are known to
confer an immunity of short duration (2–3 years) and are therefore
not recommended in expanded vaccination programs [6,29]. But
this characteristic may not impact the use of fractional dosing in a
reactive mass vaccination campaign aimed at preventing further
new cases during an ongoing epidemic. Study subjects in this trial
were followed up to 2 years, and the duration of protection will be
addressed later on.
Several potential limitations of this study must be addressed.
Tolerability data were excellent; however, the weekly visits
between the vaccination and four weeks later may not have been
optimal to capture adverse events often occurring in the first days
after vaccination. HIV testing was not systematically performed.
Considering the epidemiological indicators of HIV in the adult
population aged 15–49 years (HIV prevalence rate 6.7% [5.7–
7.6]) [30], and the exclusion criteria of known or suspected cases in
our study population, the impact of HIV is unlikely to be
noticeable. Injections of fractional doses with ‘‘insulin syringes’’
were considered relatively simple to perform in the field for the 1/
5 (0.1 mL) dose, but the 1/10 (0.05 mL) dose was more difficult to
inject. Such difficulty may have hampered the delivery of the 1/10
fractional dose. This evaluation was based on the informal
evaluation from the study team. Considering the absence of
difficulties to inject 1/5 of the dose providing the use of
appropriate syringes and training, health workers engaged in an
outbreak response during an epidemic should not faced major
problems to implement this vaccination. The unexpected high
background rate of immunity to serogroup A in the study
Table 2. Description of individual exclusions by population (MITT, PP, Safety population) and randomized group
Reason for exclusion Number of volunteers Randomized group Excluded for
Received 1/10 instead of 1/5 1 1/5 dose PP all serogroups
Withdrew consent before vaccination 1 1/10 dose MITT, PP, Safety Analysis all serogroups
Mis-stratified* 3 2 in 1/5 dose and 1 in 1/10 PP all serogroups
Carrier of W135** 2 1in Full dose and 1 in 1/10 dose PP for W135
Malnourished (weight/height ,22 Z-score) 1 Full dose PP all serogroups
*Allocated to the wrong age group.
**Volunteers presenting a carriage of W135 between the vaccination and four weeks later.
doi:10.1371/journal.pntd.0000342.t002
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population has been a constraint to demonstrate the impact of the
vaccination for this serogroup. Despite the fact that no large
outbreak of meningococcal meningitis due to serogroup A had
been declared in southern Uganda in the years prior to the study,
it is likely that the strain was circulating in the region, following the
outbreaks of serogroup A in neighbouring countries, Burundi and
Rwanda in 2002 [31].
Quality control of the SBA titers showed satisfactory results for
serogroups A, C, and Y. However, a discrepancy was found for the
W135 serogroup. This discrepancy was found to be due to the use
of a different strain between the two laboratories. Once repeated
with same strain, there was no significant difference between the
results of the two laboratories (p = 0.31). As the proportion of
responders for serogroup W135 was the same in the two
Table 3. Proportion of responders per serogroup and per population and SBA GMT at 4 weeks after vaccination
Analyses Dose Group Proportion of Responders SBA Titers four weeks after vaccination
n/N % 95% CI GMT 95% CI
Serogroup A
MITT Full 249/289 86.2 82.2–90.2 3607.1 2952.8–4406.3
1/5 dose 173/224 77.2 71.7–82.7 2035.4 1600.1–2589.0
1/10 dose 159/230 69.1 63.2 -75.0 1367.6 1083.1–1726.8
PP Full 247/287 86.1 82.1–90.1 3612.6 2953.3–4419.1
1/5 dose 172/222 77.5 72.0–83.0 2054.4 1612.2–2618.0
1/10 dose 159/229 69.4 63.5–75.3 1369.3 1083.3–1730.7
Non immune Full 140/148 94.6 91.0–98.2 1918.0 1426.0–2579.8
1/5 dose 94/102 92.2 87.0–97.4 852.3 573.2–1267.5
1/10 dose 98/111 88.3 82.4–94.2 754.1 495.3–1148.1
Serogroup W135
MITT Full 269/289 93.1 90.2–96.0 2190.3 1728.9–2774.6
1/5 dose 212/224 94.6 91.7–97.5 2029.1 1573.7–2616.2
1/10 dose 220/231 95.2 92.5–97.9 2422.7 1979.9–2964.6
PP Full 267/286 93.4 90.5–96.3 2175.9 1714.2–2762.0
1/5 dose 210/222 94.6 91.6–97.6 2041.6 1582.2–2634.5
1/10 dose 219/229 95.6 93.0–98.2 2426.3 1979.7–2973.7
Non immune Full 207/221 93.7 90.5–96.9 1539.5 1160.0–2043.2
1/5 dose 168/178 94.4 91.0–97.8 1517.4 1129.3–2039.0
1/10 dose 172/177 97.2 94.8–99.6 2008.3 1583.0–2547.9
Serogroup C
MITT Full 259/284 91.2 87.9–94.5 1168.3 911.0–1498.2
1/5 dose 179/222 80.6 75.4–85.8 472.1 332.3–670.6
1/10 dose 171/223 76.7 71.2–82.2 399.3 277.1–575.4
PP Full 257/282 91.1 87.8–94.4 1175.1 914.9–1509.3
1/5 dose 177/220 80.4 75.2–85.6 467.3 328.0–665.8
1/10 dose 170/222 76.6 71.1–82.1 396.3 274.6–572.0
Non immune Full 252/271 93.0 90.0–96.0 1108.5 858.4–1431.5
1/5 dose 172/211 81.5 76.3–86.7 412.2 288.2–589.6
1/10 dose 156/202 77.2 71.4–83.0 315.6 214.8–463.8
Serogroup Y
MITT Full 242/286 84.6 80.4–88.8 936.2 673.7–1301.0
1/5 dose 185/224 82.6 77.7–87.5 772.7 529.2–1128.2
1/10 dose 194/231 84.0 79.3–88.7 822.6 569.8–1187.5
PP Full 240/284 84.5 80.3–88.7 924.2 663.8–1286.7
1/5 dose 183/222 82.4 77.4–87.4 768.3 524.4–1125.6
1/10 dose 193/230 83.9 79.2–88.6 816.8 565.1–1180.8
Non immune Full 238/282 84.4 80.2–88.6 916.8 657.3–1278.8
1/5 dose 175/214 81.8 76.7–86.9 687.5 466.1–1014.1
1/10 dose 191/228 83.8 79.0–88.6 798.1 551.1–1155.7
doi:10.1371/journal.pntd.0000342.t003
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laboratories and the source of the discrepancy was identified, we
believe that our overall results of serogroup W135 are validated.
Baby rabbit complement was used in the SBA assays in
accordance with international standard protocols to evaluate
polysaccharide vaccines against meningococcal disease, but SBA
with human complement might be more relevant to elucidate the
immune response after disease and vaccination. Additional insight
would be gained by assaying these sera in a human complement
SBA assay, and such analyses are ongoing.
The two prevailing serogroups that cause N. meningitidis
epidemics in the African Meningitis Belt are A and W135, and
serogroups C and Y are not presently reported as the causal agent
of meningitis epidemics in the region [6]. The WHO states that
problems regarding the availability and affordability of protective
Table 4. Non-inferiority analysis results of SBA responders
per serogroup and analyses
Total population Non-immune population
Serogroup A MITT (n = 743) (n = 361)
Diff. 95%CI Diff. 95%CI
Full dose vs 1/5 +8.9% [+2.1%, +15.7%] +2.4% [23.9%, +8.8%]
Full dose vs 1/10 +17.0% [+9.8%, +24.2%] +6.3% [20.7%, +13.3%]
Serogroup W135 MITT (n = 744) (n = 576)
Diff. 95%CI Diff. 95%CI
Full dose vs 1/5 21.6% [25.7%, +2.6%] 20.7% [25.4%, +3.9%]
Full dose vs 1/10 22.2% [26.2%, +1.9%] 23.5% [27.5%, +0.5%]
Serogroup C MITT (n = 729) (n = 684)
Diff. 95%CI Diff. 95%CI
Full dose vs 1/5 +10.6% [+4.4%;+16.7%] +11.5% [+5.4%;+17.5%]
Full dose vs 1/10 +14.5% [+8.1%;+21.0%] +15.8% [+9.2% ; +22.3%]
Serogroup Y MITT (n = 741) (n = 724)
Diff. 95%CI Diff. 95%CI
Full dose vs 1/5 +2.0% [24.5%;+8.5%] +2.6% [24.1%;+9.3%]
Full dose vs 1/10 +0.6% [25.7%;+6.9%] +0.6% [25.8%;+7.0%]
doi:10.1371/journal.pntd.0000342.t004
Table 5. Logistic regression results of age effect on
responder per serogroup and per arm–MITT population
Serogroups Full dose 1/5 dose 1/10 dose
Age.5 vs. #5
years old OR (95% CI) OR (95% CI) OR (95% CI)
Serogroup A 2.07 (0.99;4.31) 0.62 (0.27; 1.42) 0.79 (0.39; 1.61)
Serogroup W135 2.78 (1.08; 7.15) 2.81 (0.85; 9.28) 0.37 (0.05; 2.95)
Serogroup C 3.37 (1.44; 7.87) 2.83 (1.36; 5.87) 1.66 (0.81; 3.44)
Serogroup Y 1.99 (0.98; 4.05) 1.84 (0.85; 3.98) 2.46 (1.14; 5.30)
doi:10.1371/journal.pntd.0000342.t005
Figure 2. ELISA IgG concentrations per serogroup and per arm before the vaccination and four weeks later in the MITT population
(GMC with superior limit of 95%CI). GMC=geometric mean concentration. P,0.001 for all comparisons between the vaccination and four weeks
later for all serogroups.
doi:10.1371/journal.pntd.0000342.g002
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meningococcal vaccines over the coming years need to be
addressed urgently [6]. A risk-benefit analysis of the use of
fractional doses should guide decision-makers. Similar strategies with
other vaccines have already proved successful [32]. Assuming 90%,
short-term protection by the licensed meningococcal polysaccharide
vaccines, and a conservative protection of 80% using a reduced 1/5
dose, the same amount of resources invested in vaccine purchase
would protect 4.4 times more subjects. Although the cost of
immunization is not a primary interest of this strategy in the context
of a global shortage, the use of a fractional dose would decrease the
cost per person vaccinated by approximately half (data not shown).
While the advent of conjugate A vaccine will largely contribute to
control serogroup A outbreaks in Africa, the scale-up of its
production will not cover the entire ‘‘meningitis belt’’ target
population over the next 3 to 5 years (Laforce M., Meningitis
Vaccine Project, personal communication January 2008). Consid-
ering the current shortage of meningococcal vaccines for Africa and
the prevalence of serogroups A and W135, the use of 1/5 fractional
doses should be explored as an alternative strategy in mass
vaccination campaigns.
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